Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
957.76
+5.36 (0.56%)
At close: Nov 17, 2026, 4:00 PM EST
965.00
+7.24 (0.76%)
After-hours: Nov 17, 2026, 6:14 PM EST
Regeneron Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 28 analysts polled by S&P Global, Regeneron Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $990.81. The average 1-year stock price forecast is 3.45% higher than the current stock price, while the lowest is $812 (-15.22%) and the highest is $1,175 (+22.68%).
Price Target: $990.81 (+3.45%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Regeneron Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 16 | 14 | 14 | 13 | 15 | 15 |
| Buy | 5 | 4 | 4 | 4 | 4 | 4 |
| Hold | 8 | 10 | 9 | 9 | 8 | 9 |
| Sell | 0 | 0 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 29 | 28 | 28 | 27 | 28 | 28 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $917 → $1,075 | Buy | Maintains | $917 → $1,075 | +12.24% | Nov 17, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $1,175 | Buy | Maintains | $1,175 | +22.68% | Nov 11, 2026 |
| Citi | Citi | Hold Maintains $825 | Hold | Maintains | $825 | -13.86% | Nov 11, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $1,030 | Buy | Maintains | $1,030 | +7.54% | Nov 11, 2026 |
| BMO Capital | BMO Capital | Buy Maintains $920 → $1,050 | Buy | Maintains | $920 → $1,050 | +9.63% | Nov 3, 2026 |
Financial Forecast
Revenue This Year
18.81B
from 14.34B
Increased by 31.18%
Revenue Next Year
20.17B
from 18.81B
Increased by 7.19%
EPS This Year
69.09
from 44.31
Increased by 55.92%
EPS Next Year
71.10
from 69.09
Increased by 2.91%
EPS and Forward PE are based on non-GAAP adjusted numbers.